GIP / GLP-1 / glucagon triple agonist

Retatrutide

Large sponsor-reported Phase 3 weight-loss results, while composition evidence remains less mature than the scale-weight story.

M4 Evidence Maturity · Advanced Clinical

Investigational · Phase 3

Evidence reviewed: September 19, 2026Sponsor-reported Phase 3

Signal summary

Retatrutide is the clearest example of why RecompSignal separates weight efficacy from body-composition evidence maturity.

Signal interpretation: Retatrutide may become a category-defining obesity therapy. But today the evidence signal is strongest for weight loss, not for every downstream composition outcome. That difference matters.

Study details

Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.

Phase 2 obesity trial

Population: 338 adults with obesity or overweight and a weight-related condition.
Doses and administration studied: Target groups: 1, 4, 8 or 12 mg subcutaneously once weekly. Higher-dose groups used different starting doses/escalation schemes.
Duration: 48 weeks; primary endpoint at week 24
Reported finding / status: At week 48, mean weight change was -24.2% in the 12 mg group versus -2.1% with placebo.
Interpretation and limitations: Gastrointestinal events were dose-related; heart-rate increases were observed. Later phase 3 sponsor results must be read separately from this published phase 2 regimen.

Source tier B · Read the original study or record

Outcome Evidence Strength

Weight change3/5

Fat-mass change0/5

Lean-mass change0/5

Strength / function benefit0/5

Weight: published controlled efficacy evidence plus later sponsor phase 3 reports. Fat, lean and function: the cited weight trial does not establish selective composition or functional benefit.

Editorial evidence ratings for the cited outcomes, not effect size or treatment recommendations. A lean-mass score may describe loss. 0 means not established in the reviewed evidence, not proof of no effect. Read the rubric.

What is actually established?

Lilly reported average 28.3% weight loss at 80 weeks for the 12 mg group in TRIUMPH-1.
In July 2026, Lilly reported additional positive Phase 3 TRIUMPH-2 and TRIUMPH-3 results.
Lilly has stated that it plans a U.S. regulatory submission in Q1 2027.

What is not established?

Retatrutide remains investigational and is not FDA-approved.
Detailed peer-reviewed Phase 3 body-composition evidence is not yet as mature as the weight-loss evidence.
Strong weight loss does not prove superior lean-mass preservation.

Still being studied

Detailed peer-reviewed Phase 3 composition, lean-tissue and function outcomes—and how those signals compare with established therapies.

Best human evidence at a glance

Evidence	Population	Comparator & duration	Outcome measured	Evidence state
TRIUMPH-1	Adults with obesity or overweight, without diabetes	Placebo · 80 weeks	Scale weight and metabolic outcomes	Sponsor-reported Full peer-reviewed Phase 3 detail remains important.
TRIUMPH-2 / 3	Additional Phase 3 populations	Controlled Phase 3 programs	Weight and cardiometabolic outcomes	Sponsor-reported Composition-specific interpretation remains limited.

Measurement context: A large scale-weight change cannot establish how much came from fat, lean tissue, water or glycogen. Direct DXA, MRI or CT outcomes must be evaluated separately when reported.

Safety evidence context

Safety and tolerability evidence is still developing within an investigational Phase 3 program. Sponsor summaries are not a substitute for complete peer-reviewed and regulatory review.

Interpretation boundary

This card tracks research and does not recommend investigational use, dosing or sourcing.

Sep 11, 2026

What changed: Added explicit maturity-versus-outcome scoring, study context, measurement limitations and sponsor-reported labeling.

Related explainerPipeline

Why the triple-agonist mechanism matters—and what it does not prove.

Use this short explainer as an entry point, then return to the source-labeled evidence above.

Explore the pipeline

Evidence sources

A = regulatory/official • B = peer-reviewed randomized/meta-analysis • C = peer-reviewed review/observational • D = registered trial • E = sponsor-reported • F = preclinical

Source tier E: Sponsor-reported Phase 3 results
TRIUMPH-1 topline results

Source tier E: Sponsor-reported Phase 3 results
TRIUMPH-2 and TRIUMPH-3; Q1 2027 submission target

Educational use only. This page summarizes research evidence and regulatory status. Study doses describe research, not prescribing instructions. This page does not provide personalized dosing, self-use protocols, sourcing, or a recommendation to use this therapy.